

# **Glioblastoma Multiforme Treatment-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data**

<https://marketpublishers.com/r/G44E4E2D306EN.html>

Date: January 2018

Pages: 157

Price: US\$ 3,680.00 (Single User License)

ID: G44E4E2D306EN

## **Abstracts**

### Report Summary

Glioblastoma Multiforme Treatment-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Glioblastoma Multiforme Treatment industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Glioblastoma Multiforme Treatment 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Glioblastoma Multiforme Treatment worldwide and market share by regions, with company and product introduction, position in the Glioblastoma Multiforme Treatment market

Market status and development trend of Glioblastoma Multiforme Treatment by types and applications

Cost and profit status of Glioblastoma Multiforme Treatment, and marketing status

Market growth drivers and challenges

The report segments the global Glioblastoma Multiforme Treatment market as:

Global Glioblastoma Multiforme Treatment Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)  
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)  
Asia Pacific (China, Japan, India, Southeast Asia and Australia)  
Latin America (Brazil, Argentina and Colombia)  
Middle East and Africa

Global Glioblastoma Multiforme Treatment Market: Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Bevacizumab (Avastin)  
Temozolomide (Temodar and Temodal and Temcad)  
Carmustine (BiCNU)

Global Glioblastoma Multiforme Treatment Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Clinic

Global Glioblastoma Multiforme Treatment Market: Manufacturers Segment Analysis  
(Company and Product introduction, Glioblastoma Multiforme Treatment Sales Volume, Revenue, Price and Gross Margin):

AbbVie, Inc  
Activartis GmbH  
Agenus Inc  
Arog Pharmaceuticals, Inc  
Bristol-Myers Squibb Company  
Cavion LLC  
Celldex Therapeutics Inc  
Cortice Biosciences  
Exelixis Inc  
F. Hoffmann-La Roche Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF GLIOBLASTOMA MULTIFORME TREATMENT**

- 1.1 Definition of Glioblastoma Multiforme Treatment in This Report
- 1.2 Commercial Types of Glioblastoma Multiforme Treatment
  - 1.2.1 Bevacizumab (Avastin)
  - 1.2.2 Temozolomide (Temodar and Temodal and Temcad)
  - 1.2.3 Carmustine (BiCNU)
- 1.3 Downstream Application of Glioblastoma Multiforme Treatment
  - 1.3.1 Hospital
  - 1.3.2 Clinic
- 1.4 Development History of Glioblastoma Multiforme Treatment
- 1.5 Market Status and Trend of Glioblastoma Multiforme Treatment 2013-2023
  - 1.5.1 Global Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023
  - 1.5.2 Regional Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Glioblastoma Multiforme Treatment 2013-2017
- 2.2 Sales Market of Glioblastoma Multiforme Treatment by Regions
  - 2.2.1 Sales Volume of Glioblastoma Multiforme Treatment by Regions
  - 2.2.2 Sales Value of Glioblastoma Multiforme Treatment by Regions
- 2.3 Production Market of Glioblastoma Multiforme Treatment by Regions
- 2.4 Global Market Forecast of Glioblastoma Multiforme Treatment 2018-2023
  - 2.4.1 Global Market Forecast of Glioblastoma Multiforme Treatment 2018-2023
  - 2.4.2 Market Forecast of Glioblastoma Multiforme Treatment by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Glioblastoma Multiforme Treatment by Types
- 3.2 Sales Value of Glioblastoma Multiforme Treatment by Types
- 3.3 Market Forecast of Glioblastoma Multiforme Treatment by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Glioblastoma Multiforme Treatment by Downstream

Industry

4.2 Global Market Forecast of Glioblastoma Multiforme Treatment by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

5.1 North America Glioblastoma Multiforme Treatment Market Status by Countries

5.1.1 North America Glioblastoma Multiforme Treatment Sales by Countries (2013-2017)

5.1.2 North America Glioblastoma Multiforme Treatment Revenue by Countries (2013-2017)

5.1.3 United States Glioblastoma Multiforme Treatment Market Status (2013-2017)

5.1.4 Canada Glioblastoma Multiforme Treatment Market Status (2013-2017)

5.1.5 Mexico Glioblastoma Multiforme Treatment Market Status (2013-2017)

5.2 North America Glioblastoma Multiforme Treatment Market Status by Manufacturers

5.3 North America Glioblastoma Multiforme Treatment Market Status by Type (2013-2017)

5.3.1 North America Glioblastoma Multiforme Treatment Sales by Type (2013-2017)

5.3.2 North America Glioblastoma Multiforme Treatment Revenue by Type (2013-2017)

5.4 North America Glioblastoma Multiforme Treatment Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

6.1 Europe Glioblastoma Multiforme Treatment Market Status by Countries

6.1.1 Europe Glioblastoma Multiforme Treatment Sales by Countries (2013-2017)

6.1.2 Europe Glioblastoma Multiforme Treatment Revenue by Countries (2013-2017)

6.1.3 Germany Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.1.4 UK Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.1.5 France Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.1.6 Italy Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.1.7 Russia Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.1.8 Spain Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.1.9 Benelux Glioblastoma Multiforme Treatment Market Status (2013-2017)

6.2 Europe Glioblastoma Multiforme Treatment Market Status by Manufacturers

6.3 Europe Glioblastoma Multiforme Treatment Market Status by Type (2013-2017)

- 6.3.1 Europe Glioblastoma Multiforme Treatment Sales by Type (2013-2017)
- 6.3.2 Europe Glioblastoma Multiforme Treatment Revenue by Type (2013-2017)
- 6.4 Europe Glioblastoma Multiforme Treatment Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Glioblastoma Multiforme Treatment Market Status by Countries
  - 7.1.1 Asia Pacific Glioblastoma Multiforme Treatment Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Glioblastoma Multiforme Treatment Revenue by Countries (2013-2017)
  - 7.1.3 China Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 7.1.4 Japan Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 7.1.5 India Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 7.1.6 Southeast Asia Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 7.1.7 Australia Glioblastoma Multiforme Treatment Market Status (2013-2017)
- 7.2 Asia Pacific Glioblastoma Multiforme Treatment Market Status by Manufacturers
- 7.3 Asia Pacific Glioblastoma Multiforme Treatment Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Glioblastoma Multiforme Treatment Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Glioblastoma Multiforme Treatment Revenue by Type (2013-2017)
- 7.4 Asia Pacific Glioblastoma Multiforme Treatment Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 8.1 Latin America Glioblastoma Multiforme Treatment Market Status by Countries
  - 8.1.1 Latin America Glioblastoma Multiforme Treatment Sales by Countries (2013-2017)
  - 8.1.2 Latin America Glioblastoma Multiforme Treatment Revenue by Countries (2013-2017)
  - 8.1.3 Brazil Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 8.1.4 Argentina Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 8.1.5 Colombia Glioblastoma Multiforme Treatment Market Status (2013-2017)
- 8.2 Latin America Glioblastoma Multiforme Treatment Market Status by Manufacturers
- 8.3 Latin America Glioblastoma Multiforme Treatment Market Status by Type (2013-2017)
  - 8.3.1 Latin America Glioblastoma Multiforme Treatment Sales by Type (2013-2017)

- 8.3.2 Latin America Glioblastoma Multiforme Treatment Revenue by Type (2013-2017)
- 8.4 Latin America Glioblastoma Multiforme Treatment Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 9.1 Middle East and Africa Glioblastoma Multiforme Treatment Market Status by Countries
  - 9.1.1 Middle East and Africa Glioblastoma Multiforme Treatment Sales by Countries (2013-2017)
  - 9.1.2 Middle East and Africa Glioblastoma Multiforme Treatment Revenue by Countries (2013-2017)
  - 9.1.3 Middle East Glioblastoma Multiforme Treatment Market Status (2013-2017)
  - 9.1.4 Africa Glioblastoma Multiforme Treatment Market Status (2013-2017)
- 9.2 Middle East and Africa Glioblastoma Multiforme Treatment Market Status by Manufacturers
- 9.3 Middle East and Africa Glioblastoma Multiforme Treatment Market Status by Type (2013-2017)
  - 9.3.1 Middle East and Africa Glioblastoma Multiforme Treatment Sales by Type (2013-2017)
  - 9.3.2 Middle East and Africa Glioblastoma Multiforme Treatment Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Glioblastoma Multiforme Treatment Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT**

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Glioblastoma Multiforme Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 11 GLIOBLASTOMA MULTIFORME TREATMENT MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

- 11.1 Production Volume of Glioblastoma Multiforme Treatment by Major Manufacturers
- 11.2 Production Value of Glioblastoma Multiforme Treatment by Major Manufacturers
- 11.3 Basic Information of Glioblastoma Multiforme Treatment by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Glioblastoma Multiforme Treatment Major Manufacturer

11.3.2 Employees and Revenue Level of Glioblastoma Multiforme Treatment Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

## **CHAPTER 12 GLIOBLASTOMA MULTIFORME TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

12.1 AbbVie, Inc

12.1.1 Company profile

12.1.2 Representative Glioblastoma Multiforme Treatment Product

12.1.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of AbbVie, Inc

12.2 Activartis GmbH

12.2.1 Company profile

12.2.2 Representative Glioblastoma Multiforme Treatment Product

12.2.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Activartis GmbH

12.3 Agenus Inc

12.3.1 Company profile

12.3.2 Representative Glioblastoma Multiforme Treatment Product

12.3.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Agenus Inc

12.4 Arog Pharmaceuticals, Inc

12.4.1 Company profile

12.4.2 Representative Glioblastoma Multiforme Treatment Product

12.4.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Arog Pharmaceuticals, Inc

12.5 Bristol-Myers Squibb Company

12.5.1 Company profile

12.5.2 Representative Glioblastoma Multiforme Treatment Product

12.5.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

12.6 Cavion LLC

12.6.1 Company profile

- 12.6.2 Representative Glioblastoma Multiforme Treatment Product
- 12.6.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cavion LLC
- 12.7 Celldex Therapeutics Inc
  - 12.7.1 Company profile
  - 12.7.2 Representative Glioblastoma Multiforme Treatment Product
  - 12.7.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Celldex Therapeutics Inc
- 12.8 Cortice Biosciences
  - 12.8.1 Company profile
  - 12.8.2 Representative Glioblastoma Multiforme Treatment Product
  - 12.8.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cortice Biosciences
- 12.9 Exelixis Inc
  - 12.9.1 Company profile
  - 12.9.2 Representative Glioblastoma Multiforme Treatment Product
  - 12.9.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Exelixis Inc
- 12.10 F. Hoffmann-La Roche Ltd
  - 12.10.1 Company profile
  - 12.10.2 Representative Glioblastoma Multiforme Treatment Product
  - 12.10.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT**

- 13.1 Industry Chain of Glioblastoma Multiforme Treatment
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT**

- 14.1 Cost Structure Analysis of Glioblastoma Multiforme Treatment
- 14.2 Raw Materials Cost Analysis of Glioblastoma Multiforme Treatment
- 14.3 Labor Cost Analysis of Glioblastoma Multiforme Treatment
- 14.4 Manufacturing Expenses Analysis of Glioblastoma Multiforme Treatment



## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

### 16.1 Methodology/Research Approach

#### 16.1.1 Research Programs/Design

#### 16.1.2 Market Size Estimation

#### 16.1.3 Market Breakdown and Data Triangulation

### 16.2 Data Source

#### 16.2.1 Secondary Sources

#### 16.2.2 Primary Sources

### 16.3 Reference

## I would like to order

Product name: Glioblastoma Multiforme Treatment-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/G44E4E2D306EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G44E4E2D306EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

